To your comment JBuff, Pfizer's average price to sales ratio for the last 5 years has been 4.594:1. The range is 3.2 to 6.6  I doubt RVX can command the same market respect as Pfizer (maybe on an intitial frothy push though) but with a covid therapeutic and sales of $700M even if RVX could achieve the PFE minimum that would result in $2B of market cap attributable to sales. If Apabetalone turns out to be a covid therapeutic there will be global not just N. American sales and there will still be the rest of the RVX program which will receive a boost in attention. The whole package could become highly valued by the market with covid therapeutic sales and if the company improves on its management/communication performance.